NCT03233009View on ClinicalTrials.gov

To Investigate Primary Irritation Potential of Four Skin Serum Products on Human Subjects Assessed by 24 Hour Patch Test

NACompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

May 22, 2017

Primary Completion Date

May 26, 2017

Study Completion Date

May 26, 2017

Conditions
Skin Care
Interventions
OTHER

Experimental Daily Defense Serum A

Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).

OTHER

Experimental Daily Defense Serum C

Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).

OTHER

Experimental Daily Defense Serum G

Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).

OTHER

Experimental Daily Defense Serum N

Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).

OTHER

Saline Solution Sodium Chloride

Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).

Trial Locations (2)

13271-130

GSK Investigational Site, Valinhos

13271-

GSK Investigational Site, Valinhos

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY